Concord Medical Services Holdings Limited

For the first half of 2016, total revenues were RMB254.6 million, down 21.7% from RMB325.2 million a year earlier. Gross profit was RMB101.6 million, down 33.9% from RMB153.6 million, and gross margin was 39.9% versus 47.2% last year. Net loss attributable to ordinary shareholders was RMB50.4 million compared with net income of RMB65.1 million in the prior-year period, and basic and diluted loss per ADS were RMB1.15, or $0.17, versus profit per ADS of RMB1.45 and RMB1.44. Adjusted EBITDA was RMB68.6 million, down 49.1% from RMB134.8 million. By segment, network business net revenues were RMB246.7 million, down 22.2%, with gross profit of RMB108.8 million and gross margin of 44.1%; Concord Cancer Hospital generated RMB8 million of net revenue, RMB15.2 million of cost of service, and a gross loss of RMB7.2 million. The company said it operated 123 cooperative centers in 52 cities as of June 30, 2016 and had agreements for one additional center. Management did not give numeric full-year or next-quarter guidance on the call, but said it would keep improving cost efficiency, selectively convert centers into fully owned facilities, and accelerate Meizhongjiahe hospital expansion in cities including Wuxi, Hangzhou, Nanchang, and Shanghai.

Jianyu Yang said the quarter and first half were hit by both external regulatory pressure and internal transformation efforts away from the old cooperative-center model. He emphasized that the loss narrowed quarter over quarter in Q2 and framed the strategy shift as building a network of wholly owned imaging diagnosis and radiotherapy hospitals, led by Datong Meizhongjiahe Cancer Hospital, which opened preliminarily in May. He also highlighted continued collaboration with MD Anderson and said the company would keep pushing long-term development despite a tougher regulatory environment.

Kong Yap focused on the financial decline and the drivers behind it, citing first-half revenue of RMB254.6 million, gross profit of RMB101.6 million, and adjusted EBITDA of RMB68.6 million. She said the network business continued to face uncertainties from regulation, center closures, and revenue-sharing changes, while Concord Cancer Hospital produced RMB8 million of revenue and a RMB7.2 million gross loss. She also noted liquidity of RMB3.5 billion in bank credit lines, with RMB1.1 billion utilized, and said the company would improve cost efficiency and selectively transform existing centers into fully owned ones. She disclosed the board had received a non-binding going-private proposal at $1.73 per Class A share or $5.91 per ADS, and said it was under review with advisors.

There was no substantive analyst Q&A in the transcript, so the main follow-up items were management’s comments on strategy, Singapore hospital performance, and the going-private proposal. Management said the board was reviewing the proposal from parties including Chairman and CEO Jianyu Yang and affiliated vehicles, and would decide what best serves shareholders. On operations, they reiterated that Datong was the first step in the Meizhongjiahe network, that patient visits from mainland China to Singapore had begun to improve since March, and that renovations and radiotherapy expansion at Concord Cancer Hospital were underway.